Switching off cancer genes

 
PROGEN Pharmaceuticals is making progress in a technology aiming to ‘switch off’ cancerous genes. 
A pre-clinical study found that Progen’s epigenetic technology is able to inhibit tumour-suppressing enzymes. CEO Justus Homburg is excited about the results.
“In epigenetics we try to switch genes to change how that cell behaves, how to stop it being cancerous rather than saying cancer cells are bad and let’s kill them off — it represents a big shift in the paradigm and that’s why epigenetics is so exciting,” explains Homburg.
But drug development is a lengthy process and Homburg predicts it could be another six years before the product PG11144 is fully developed and on the market as the first, second and third phases of trials still need to be carried out.
“Could it be a long term development? Yes, that could very well be the case, but it’s something well worth pursuing because it is a dramatic change,” he says.
Homburg points out the very risky nature of the drug development industry but he believes the technology’s potential is backed up by the data that shows it does have an effect on tumours.
“We think there’s an opportunity out there, but the vast majority of drug developments don’t succeed,” he says.
“We may be only able to target a specific cancer or a specific disease of a specific cancer – there’s a lot to learn but it’s potentially quite groundbreaking.”
Homburg is confident that Progen is in a good financial position and is comfortable with the company’s patent on the technology.
“One of the things to bear in mind is that we’ve been through a lot of corporate turmoil, but we have been able to put an awful lot of that behind ourselves and during that time pursued research in all of our products,” he says.
“These latest findings prove we have the technology, the expertise and the resources to progress our strong product pipeline.”

Get our daily business news

Sign up to our free email news updates.

 
Whitefox Recruitment founder Luke Hemmings making strides as a careers leader
Partner Content
After relocating his Canberra-founded company Whitefox Recruitment to the Gold Coast la...
Whitefox Recruitment
Advertisement

Related Stories

ASIC secures its first court win for greenwashing against US giant Vanguard

ASIC secures its first court win for greenwashing against US giant Vanguard

The Australian corporate watchdog has caught out one of the world&r...

Medicinal cannabis group Althea shaves $1.5m from its cost base through staff cutbacks

Medicinal cannabis group Althea shaves $1.5m from its cost base through staff cutbacks

Australian-founded medicinal cannabis company Althea Group (ASX: AG...

Charter Hall snares 15pc stake in Hotel Property Investments for $97m from 360 Capital

Charter Hall snares 15pc stake in Hotel Property Investments for $97m from 360 Capital

Listed funds manager 360 Capital Group (ASX: TGP) has offloaded its...

The party’s over: Splendour in the Grass festival cancelled for 2024

The party’s over: Splendour in the Grass festival cancelled for 2024

Splendour in the Grass, Australia’s largest winter music fest...